IceCure Medical Ltd. has reported its financial results for the first half of 2025, revealing a decline in revenue and gross profit compared to the same period in 2024. The revenue for the six months ended June 30, 2025, was $1.25 million, a decrease from $1.754 million for the same period in 2024. This decline included a $100,000 recognition from a distribution agreement and other services in Japan in 2024. Additionally, product sales worth over $200,000 scheduled for the second quarter of 2025 were delayed due to the Israel-Iran conflict, with payments recorded as deferred sales. Gross profit for the six months ended June 30, 2025, was $349,000, down from $799,000 in the same period in 2024. The gross margin also decreased to 28% from 46% in the previous year. The non-GAAP gross profit stood at $349,000 compared to $699,000 for the six months ended June 30, 2024, with a non-GAAP gross margin of 28%, down from 42% in 2024. This reduction in non-GAAP gross profit and margin was primarily due to a 24% decrease in revenue from sales of ProSense® systems and disposable probes. A significant business update includes a successful $10 million rights offering, which was two-times oversubscribed, providing a cash runway as IceCure Medical anticipates an FDA marketing authorization decision for ProSense® in women aged 70+ with early-stage low-risk breast cancer.